oral, selective beta-catenin/CBP PPI inhibitor synergy w/ PD-1i in model, in Ph. I for cancer opt. of prior peptidomimetic candidate Cancer Res., Jan. 6, 2021 Eisai Co., Ltd., Tsukuba, JP